Atlas Trials

A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

Clinical trial NCT07589244 · RECRUITING

Trial details

NCT number
NCT07589244
Sponsor
Guangzhou Virotech Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
HCC
Start date
2026-05-13
Primary completion
2028-12-31
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.